Increasing the Positive Yield of Hereditary Cancer Testing with DNA and RNA - Ambry Genetics

Explore how concurrent DNA and RNA genetic testing enhances the detection of clinically-actionable variants and reduces variants of unknown significance (VUS) in hereditary cancer testing. Learn about the latest advancements in diagnostic yield improvement through this informative webinar presented by Dr. Rachid Karam and moderated by Tara Namey, MS, LCGC. Discover the benefits of RNA sequencing in blood, understand the workflow and limitations of this approach, and examine retrospective analyses of variants. Gain insights into how RNA can detect novel variants, review new case detection data, and understand the impact on DNA analysis and variant assessment. Conclude with recommendations and a Q&A session to deepen your understanding of this cutting-edge approach to increasing the positive yield of hereditary cancer genetic testing.